CATX Stock Overview
Develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Perspective Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$12.66 |
52 Week High | US$19.05 |
52 Week Low | US$2.20 |
Beta | 1.44 |
11 Month Change | -19.11% |
3 Month Change | -1.94% |
1 Year Change | 370.98% |
33 Year Change | 103.86% |
5 Year Change | 308.39% |
Change since IPO | 26.60% |
Recent News & Updates
Recent updates
Shareholder Returns
CATX | US Biotechs | US Market | |
---|---|---|---|
7D | -5.2% | 1.1% | 1.0% |
1Y | 371.0% | 20.8% | 33.6% |
Return vs Industry: CATX exceeded the US Biotechs industry which returned 19.7% over the past year.
Return vs Market: CATX exceeded the US Market which returned 31.9% over the past year.
Price Volatility
CATX volatility | |
---|---|
CATX Average Weekly Movement | 9.7% |
Biotechs Industry Average Movement | 9.7% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 14.8% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CATX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CATX's weekly volatility (10%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1998 | 118 | Thijs Spoor | www.perspectivetherapeutics.com |
Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans.
Perspective Therapeutics, Inc. Fundamentals Summary
CATX fundamental statistics | |
---|---|
Market cap | US$893.42m |
Earnings (TTM) | -US$52.16m |
Revenue (TTM) | US$1.46m |
583.1x
P/S Ratio-16.4x
P/E RatioIs CATX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CATX income statement (TTM) | |
---|---|
Revenue | US$1.46m |
Cost of Revenue | US$0 |
Gross Profit | US$1.46m |
Other Expenses | US$53.63m |
Earnings | -US$52.16m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.77 |
Gross Margin | 100.00% |
Net Profit Margin | -3,562.98% |
Debt/Equity Ratio | 0.5% |
How did CATX perform over the long term?
See historical performance and comparison